Cargando…

Time to Achieving Clinically Significant Outcomes after Meniscal Allograft Transplantation

OBJECTIVES: Meniscal allograft transplantation (MAT) is a surgical treatment option for patients with meniscus deficiencies. Prior studies have defined clinically significant outcomes such as minimal clinical important difference (MCID) and patient acceptable symptomatic state (PASS) for commonly ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Huddleston, Hailey, Mehta, Nabil, Polce, Evan, Gilat, Ron, Alzein, Mohamad, Parvaresh, Kevin, Verma, Nikhil, Cole, Brian, Yanke, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327249/
http://dx.doi.org/10.1177/2325967121S00205
_version_ 1783732035040313344
author Huddleston, Hailey
Mehta, Nabil
Polce, Evan
Gilat, Ron
Alzein, Mohamad
Parvaresh, Kevin
Verma, Nikhil
Cole, Brian
Yanke, Adam
author_facet Huddleston, Hailey
Mehta, Nabil
Polce, Evan
Gilat, Ron
Alzein, Mohamad
Parvaresh, Kevin
Verma, Nikhil
Cole, Brian
Yanke, Adam
author_sort Huddleston, Hailey
collection PubMed
description OBJECTIVES: Meniscal allograft transplantation (MAT) is a surgical treatment option for patients with meniscus deficiencies. Prior studies have defined clinically significant outcomes such as minimal clinical important difference (MCID) and patient acceptable symptomatic state (PASS) for commonly administered patient reported outcome measures (PROMs) after MAT. The purpose of this study was to determine the time to achieving MCID and PASS and to identify any risk factors affecting achievement in patients undergoing MAT. METHODS: A prospectively maintained MAT registry was retrospectively reviewed from April 2014-May 2020. Patients who underwent revision MAT or did not complete preoperative PROMs were excluded. International Knee Documentation Committee (IKDC) and Knee Injury and Osteoarthritis Outcome Scores (KOOS) were administered preoperatively and at 6-months, 1-year, and 2-years postoperatively. Previously defined MCID and PASS thresholds were utilized and Kaplan-Meier survival curve analysis with interval censoring was used to calculate the cumulative percentages of MCID, and PASS achievement at each follow-up time interval (5-7, 11-13, and 23-25 months). RESULTS: Eighty-four patients (mean age: 28.2±9.7) were included. Time to MCID and PASS is presented in Table 1. Previously reported PASS values for KOOS Pain, Symptoms, and Sport did not reach an AUC>0.70 and thus were not included in analysis. Worker’s compensation status was found to delay time to achieving MCID for all PROs (HR=0.238-0.305, P=0.008-0.020) and PASS for KOOS Symptoms (HR=0.171, P = 0.026) and IKDC (HR=1.88, P<0.001) (Table 2 and 3). Higher preoperative PRO score was associated with mildly delaying the time to achieving MCID for all PROs (HR=0.947-0.970, P<0.001), while higher preoperative PRO scores were associated with shorter time to achieving PASS on KOOS Symptoms and KOOS QOL (HR=1.030-1.043, P=0.001). Greater BMI (HR=0.946, P=0.020) and the number of focal chondral defects (HR=0.083-0.255, P=0.007-0.029) was associated with delayed MCID for KOOS ADL and QOL, respectively, while concomitant realignment surgery decreased time to MCID on KOOS Sports (HR=2.542, P=0.008). CONCLUSIONS: This study defined the time to achieving MCID and PASS on IKDC and KOOS subscores for patients undergoing MAT. Worker’s compensation status, BMI, and the presence of focal chondral defects may prolong time to achievement of MCID and PASS after MAT.
format Online
Article
Text
id pubmed-8327249
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-83272492021-08-09 Time to Achieving Clinically Significant Outcomes after Meniscal Allograft Transplantation Huddleston, Hailey Mehta, Nabil Polce, Evan Gilat, Ron Alzein, Mohamad Parvaresh, Kevin Verma, Nikhil Cole, Brian Yanke, Adam Orthop J Sports Med Article OBJECTIVES: Meniscal allograft transplantation (MAT) is a surgical treatment option for patients with meniscus deficiencies. Prior studies have defined clinically significant outcomes such as minimal clinical important difference (MCID) and patient acceptable symptomatic state (PASS) for commonly administered patient reported outcome measures (PROMs) after MAT. The purpose of this study was to determine the time to achieving MCID and PASS and to identify any risk factors affecting achievement in patients undergoing MAT. METHODS: A prospectively maintained MAT registry was retrospectively reviewed from April 2014-May 2020. Patients who underwent revision MAT or did not complete preoperative PROMs were excluded. International Knee Documentation Committee (IKDC) and Knee Injury and Osteoarthritis Outcome Scores (KOOS) were administered preoperatively and at 6-months, 1-year, and 2-years postoperatively. Previously defined MCID and PASS thresholds were utilized and Kaplan-Meier survival curve analysis with interval censoring was used to calculate the cumulative percentages of MCID, and PASS achievement at each follow-up time interval (5-7, 11-13, and 23-25 months). RESULTS: Eighty-four patients (mean age: 28.2±9.7) were included. Time to MCID and PASS is presented in Table 1. Previously reported PASS values for KOOS Pain, Symptoms, and Sport did not reach an AUC>0.70 and thus were not included in analysis. Worker’s compensation status was found to delay time to achieving MCID for all PROs (HR=0.238-0.305, P=0.008-0.020) and PASS for KOOS Symptoms (HR=0.171, P = 0.026) and IKDC (HR=1.88, P<0.001) (Table 2 and 3). Higher preoperative PRO score was associated with mildly delaying the time to achieving MCID for all PROs (HR=0.947-0.970, P<0.001), while higher preoperative PRO scores were associated with shorter time to achieving PASS on KOOS Symptoms and KOOS QOL (HR=1.030-1.043, P=0.001). Greater BMI (HR=0.946, P=0.020) and the number of focal chondral defects (HR=0.083-0.255, P=0.007-0.029) was associated with delayed MCID for KOOS ADL and QOL, respectively, while concomitant realignment surgery decreased time to MCID on KOOS Sports (HR=2.542, P=0.008). CONCLUSIONS: This study defined the time to achieving MCID and PASS on IKDC and KOOS subscores for patients undergoing MAT. Worker’s compensation status, BMI, and the presence of focal chondral defects may prolong time to achievement of MCID and PASS after MAT. SAGE Publications 2021-07-30 /pmc/articles/PMC8327249/ http://dx.doi.org/10.1177/2325967121S00205 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This open-access article is published and distributed under the Creative Commons Attribution - NonCommercial - No Derivatives License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits the noncommercial use, distribution, and reproduction of the article in any medium, provided the original author and source are credited. You may not alter, transform, or build upon this article without the permission of the Author(s). For article reuse guidelines, please visit SAGE’s website at http://www.sagepub.com/journals-permissions.
spellingShingle Article
Huddleston, Hailey
Mehta, Nabil
Polce, Evan
Gilat, Ron
Alzein, Mohamad
Parvaresh, Kevin
Verma, Nikhil
Cole, Brian
Yanke, Adam
Time to Achieving Clinically Significant Outcomes after Meniscal Allograft Transplantation
title Time to Achieving Clinically Significant Outcomes after Meniscal Allograft Transplantation
title_full Time to Achieving Clinically Significant Outcomes after Meniscal Allograft Transplantation
title_fullStr Time to Achieving Clinically Significant Outcomes after Meniscal Allograft Transplantation
title_full_unstemmed Time to Achieving Clinically Significant Outcomes after Meniscal Allograft Transplantation
title_short Time to Achieving Clinically Significant Outcomes after Meniscal Allograft Transplantation
title_sort time to achieving clinically significant outcomes after meniscal allograft transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327249/
http://dx.doi.org/10.1177/2325967121S00205
work_keys_str_mv AT huddlestonhailey timetoachievingclinicallysignificantoutcomesaftermeniscalallografttransplantation
AT mehtanabil timetoachievingclinicallysignificantoutcomesaftermeniscalallografttransplantation
AT polceevan timetoachievingclinicallysignificantoutcomesaftermeniscalallografttransplantation
AT gilatron timetoachievingclinicallysignificantoutcomesaftermeniscalallografttransplantation
AT alzeinmohamad timetoachievingclinicallysignificantoutcomesaftermeniscalallografttransplantation
AT parvareshkevin timetoachievingclinicallysignificantoutcomesaftermeniscalallografttransplantation
AT vermanikhil timetoachievingclinicallysignificantoutcomesaftermeniscalallografttransplantation
AT colebrian timetoachievingclinicallysignificantoutcomesaftermeniscalallografttransplantation
AT yankeadam timetoachievingclinicallysignificantoutcomesaftermeniscalallografttransplantation